
MODERNA, MERCK MRNA CANCER VACCINE SUCCEEDS IN PHASE 3
$MRNA and $MRK say their personalized mRNA cancer vaccine, intismeran, combined with Keytruda slowed melanoma recurrence and spread in a late-stage trial.
The study was stopped at its first interim analysis after positive results, though detailed efficacy data have not yet been released.
If the benefit holds up, this would mark the first randomized Phase 3 validation of a personalized neoantigen cancer vaccine and could significantly broaden the use of mRNA technology beyond traditional vaccines.